Directed evolution as a tool for the selection of oncolytic RNA viruses with desired phenotypes

References

• Donnelly O, Harrington K, Melcher A, Pandha H. Live viruses to treat cancer. J R Soc Med. 2013;106(8):310–314. doi:10.1177/014107681349419623824333
   PubMed Web of Science ®Google Scholar
• Altinoz MA, Guloksuz S, Elmaci I. Rabies virus vaccine as an immune adjuvant against cancers and glioblastoma: new studies may resurrect a neglected potential. Clin Transl Oncol. 2017;19(7):785–792. doi:10.1007/s12094-017-1613-628093702
   PubMed Web of Science ®Google Scholar
• Kelly E, Russell SJ. History of oncolytic viruses: genesis to genetic engineering. Mol Ther. 2007;15(4):651–659. doi:10.1038/sj.mt.630010817299401
   PubMed Web of Science ®Google Scholar
• Lichty BD, Breitbach CJ, Stojdl DF, Bell JC. Going viral with cancer immunotherapy. Nat Rev Cancer. 2014;14(8):559–567. doi:10.1038/nrc377024990523
   PubMed Web of Science ®Google Scholar
• Liu TC, Kirn D. Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions. Cancer Res. 2007;67(2):429–432. doi:10.1158/0008-5472.CAN-06-287117234747
   PubMed Web of Science ®Google Scholar
• Dolgin E. Oncolytic viruses get a boost with first FDA-approval recommendation. Nat Rev Drug Discov. 2015;14(6):369–371. doi:10.1038/nrd464326027526
   PubMed Web of Science ®Google Scholar
• Conry RM, Westbrook B, McKee S, Norwood TG. Talimogene laherparepvec: first in class oncolytic virotherapy. Hum Vaccin Immunother. 2018;14(4):839–846. doi:10.1080/21645515.2017.141289629420123
   PubMed Web of Science ®Google Scholar
• International Committee on Taxonomy of Viruses. Virus taxonomy: 2018 release. Available from: https://talk.ictvonline.org/taxonomy/. Accessed 21, 2019.
   Google Scholar
• Coombs KM. Reovirus Structure and Morphogenesis. In: Polly Roy, ed. Reoviruses: Entry, Assembly and Morphogenesis. Berlin-Heidelberg, Germany: Springer-Verlag; 2006: 117–167. doi:10.1007/3-540-30773-7
   Google Scholar
• Stevenson A, Chandranesan J. Reoviruses. In: Wallace MR, eds. Drugs and Diseases, Infectious Diseases Medscape eMedicine; 2017 Available from: https://emedicine.medscape.com/article/227348-overview. Accessed February 1, 2019.
   Google Scholar
• Nibert LM., Structure of Mammalian Reovirus particles. In: Kenneth KL, Oldstone MBA, eds. Reoviruses I, Structure, Proteins, and Geneticsc (Current Topics in Microbiology and Immunology). Vol. 1 Berlin-Heidelberg, Germany: Springer; 1998:1–30. doi:10.1007/978-3-642-72092-5
   Google Scholar
• Mohamed A, Johnston RN, Shmulevitz M. Potential for improving potency and specificity of reovirus oncolysis with next-generation reovirus variants. Viruses. 2015;7(12):6251–6278. doi:10.3390/v712293626633466
   PubMed Web of Science ®Google Scholar
• Kemp V, Hoeben RC, van den Wollenberg DJ. Exploring reovirus plasticity for improving its use as oncolytic virus. Viruses. 2015;8(1). doi:10.3390/v8010004
   Web of Science ®Google Scholar
• Comins C, Simpson GR, Relph K, Harrington KJ, Melcher A, Pandha H. Reoviral Therapy for Cancer: Strategies for Improving Antitumor Efficacy Using Radio- and Chemotherapy. In: Lattime E, Gerson S,eds.Gene Therapy of Cancer. 2nd ed., Amsterdam, Netherlands: Elsevier; 2014:185–198.
   Google Scholar
• Forrest JC, Dermody TS. Reovirus receptors and pathogenesis. J Virol. 2003;77(17):9109–9115. doi:10.1128/jvi.77.17.9109-9115.200312915527
   PubMed Web of Science ®Google Scholar
• Gong J, Sachdev E, Mita AC, Mita MM. Clinical development of reovirus for cancer therapy: an oncolytic virus with immune-mediated antitumor activity. World J Methodol. 2016;6(1):25–42. doi:10.5662/wjm.v6.i1.2527019795
   PubMedGoogle Scholar
• Bourhill T, Mori Y, Rancourt DE, Shmulevitz M, Johnston RN. Going (Reo)Viral: factors promoting successful reoviral oncolytic infection. Viruses. 2018;10(8):421. doi:10.3390/v10080421
   Web of Science ®Google Scholar
• Morris DG, Feng X, DiFrancesco LM, et al. REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin(R)) in patients with advanced solid tumors. Invest New Drugs. 2013;31(3):696–706. doi:10.1007/s10637-012-9865-z22886613
   PubMed Web of Science ®Google Scholar
• Cohn DE, Sill MW, Walker JL, et al. Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin(R)) in recurrent ovarian, tubal, or peritoneal cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017;146(3):477–483. doi:10.1016/j.ygyno.2017.07.13528756871
   PubMed Web of Science ®Google Scholar
• Noonan AM, Farren MR, Geyer SM, et al. Randomized phase 2 trial of the oncolytic virus pelareorep (Reolysin) in upfront treatment of metastatic pancreatic adenocarcinoma. Mol Ther. 2016;24(6):1150–1158. doi:10.1038/mt.2016.6627039845
   PubMed Web of Science ®Google Scholar
• Bernstein V, Ellard SL, Dent SF, et al. A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213. Breast Cancer Res Treat. 2018;167(2):485–493. doi:10.1007/s10549-017-4538-429027598
   PubMed Web of Science ®Google Scholar
• Shmulevitz M, Gujar SA, Ahn DG, Mohamed A, Lee PW. Reovirus variants with mutations in genome segments S1 and L2 exhibit enhanced virion infectivity and superior oncolysis. J Virol. 2012;86(13):7403–7413. doi:10.1128/JVI.00304-1222532697
   PubMed Web of Science ®Google Scholar
• Mohamed A, Teicher C, Haefliger S, Shmulevitz M. Reduction of virion-associated sigma1 fibers on oncolytic reovirus variants promotes adaptation toward tumorigenic cells. J Virol. 2015;89(8):4319–4334. doi:10.1128/JVI.03651-1425653434
   PubMed Web of Science ®Google Scholar
• Jabre R, Sandekian V, Lemay G. Amino acid substitutions in sigma1 and mu1 outer capsid proteins are selected during mammalian reovirus adaptation to Vero cells. Virus Res. 2013;176(1–2):188–198. doi:10.1016/j.virusres.2013.06.00723800405
   PubMed Web of Science ®Google Scholar
• Sandekian V, Lemay G. Amino acids substitutions in sigma1 and mu1 outer capsid proteins of a Vero cell-adapted mammalian orthoreovirus are required for optimal virus binding and disassembly. Virus Res. 2015;196:20–29. doi:10.1016/j.virusres.2014.11.00225445342
   PubMed Web of Science ®Google Scholar
• Lanoie D, Cote S, Degeorges E, Lemay G. A single mutation in the mammalian orthoreovirus S1 gene is responsible for increased interferon sensitivity in a virus mutant selected in Vero cells. Virology. 2018;528:73–79. doi:10.1016/j.virol.2018.12.01030578938
   PubMed Web of Science ®Google Scholar
• Barton ES, Forrest JC, Connolly JL, et al. Junction adhesion molecule is a receptor for reovirus. Cell. 2001;104(3):441–451.11239401
   PubMed Web of Science ®Google Scholar
• Human Protein Atlas. Available from: https://www.proteinatlas.org/. Accessed 2, 2019.
   Google Scholar
• Uhlen M, Bjorling E, Agaton C, et al. A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol Cell Proteomics. 2005;4(12):1920–1932. doi:10.1074/mcp.M500279-MCP20016127175
   PubMed Web of Science ®Google Scholar
• Uhlen M, Oksvold P, Fagerberg L, et al. Towards a knowledge-based Human Protein Atlas. Nat Biotechnol. 2010;28(12):1248–1250. doi:10.1038/nbt1210-124821139605
   PubMed Web of Science ®Google Scholar
• Chappell JD, Gunn VL, Wetzel JD, Baer GS, Dermody TS. Mutations in type 3 reovirus that determine binding to sialic acid are contained in the fibrous tail domain of viral attachment protein sigma1. J Virol. 1997;71(3):1834–1841.9032313
   PubMed Web of Science ®Google Scholar
• Barton ES, Connolly JL, Forrest JC, Chappell JD, Dermody TS. Utilization of sialic acid as a coreceptor enhances reovirus attachment by multistep adhesion strengthening. J Biol Chem. 2001;276(3):2200–2211. doi:10.1074/jbc.M00468020011054410
   PubMed Web of Science ®Google Scholar
• Barton ES, Youree BE, Ebert DH, et al. Utilization of sialic acid as a coreceptor is required for reovirus-induced biliary disease. J Clin Invest. 2003;111(12):1823–1833. doi:10.1172/JCI1630312813018
   PubMed Web of Science ®Google Scholar
• van den Wollenberg DJ, Dautzenberg IJ, van den Hengel SK, Cramer SJ, de Groot RJ, Hoeben RC. Isolation of reovirus T3D mutants capable of infecting human tumor cells independent of junction adhesion molecule-A. PLoS One. 2012;7(10):e48064. doi:10.1371/journal.pone.004806423110175
   PubMed Web of Science ®Google Scholar
• Matveeva OV, Chumakov PM. Defects in interferon pathways as potential biomarkers of sensitivity to oncolytic viruses. Rev Med Virol. 2018;28(6):e2008. doi:10.1002/rmv.v28.630209859
   PubMed Web of Science ®Google Scholar
• Rudd P, Lemay G. Correlation between interferon sensitivity of reovirus isolates and ability to discriminate between normal and Ras-transformed cells. J Gen Virol. 2005;86(Pt 5):1489–1497. doi:10.1099/vir.0.80628-015831962
   PubMed Web of Science ®Google Scholar
• Sandekian V, Lemay G. A single amino acid substitution in the mRNA capping enzyme lambda2 of a mammalian orthoreovirus mutant increases interferon sensitivity. Virology. 2015;483:229–235. doi:10.1016/j.virol.2015.04.02025985441
   PubMed Web of Science ®Google Scholar
• Kim M, Egan C, Alain T, et al. Acquired resistance to reoviral oncolysis in Ras-transformed fibrosarcoma cells. Oncogene. 2007;26(28):4124–4134. doi:10.1038/sj.onc.121018917213803
   PubMed Web of Science ®Google Scholar
• Kim M, Williamson CT, Prudhomme J, et al. The viral tropism of two distinct oncolytic viruses, reovirus and myxoma virus, is modulated by cellular tumor suppressor gene status. Oncogene. 2010;29(27):3990–3996. doi:10.1038/onc.2010.13720473328
   PubMed Web of Science ®Google Scholar
• Kim M, Garant KA, zur Nieden NI, et al. Attenuated reovirus displays oncolysis with reduced host toxicity. Br J Cancer. 2011;104(2):290–299. doi:10.1038/sj.bjc.660605321179029
   PubMed Web of Science ®Google Scholar
• de Leeuw O, Peeters B. Complete nucleotide sequence of Newcastle disease virus: evidence for the existence of a new genus within the subfamily Paramyxovirinae. J Gen Virol. 1999;80(Pt 1):131–136. doi:10.1099/0022-1317-80-1-1319934695
   PubMed Web of Science ®Google Scholar
• Dimitrov KM, Ramey AM, Qiu X, Bahl J, Afonso CL. Temporal, geographic, and host distribution of avian paramyxovirus 1 (Newcastle disease virus). Infect Genet Evol. 2016;39:22–34. doi:10.1016/j.meegid.2016.01.00826792710
   PubMed Web of Science ®Google Scholar
• Nelson CB, Pomeroy BS, Schrall K, Park WE, Lindeman RJ. An outbreak of conjunctivitis due to Newcastle disease virus (NDV) occurring in poultry workers. Am J Public Health Nations Health. 1952;42(6):672–678. doi:10.2105/ajph.42.6.67214924001
   PubMed Web of Science ®Google Scholar
• Fournier P, Bian H, Szeberenyi J, Schirrmacher V. Analysis of three properties of Newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation. Methods Mol Biol. 2012;797:177–204. doi:10.1007/978-1-61779-340-0_1321948477
   PubMedGoogle Scholar
• Zamarin D, Palese P. Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions. Future Microbiol. 2012;7(3):347–367. doi:10.2217/fmb.12.422393889
   PubMed Web of Science ®Google Scholar
• Matveeva OV, Guo ZS, Shabalina SA, Chumakov PM. Oncolysis by paramyxoviruses: multiple mechanisms contribute to therapeutic efficiency. Mol Ther Oncolytics. 2015;2:15011. doi:10.1038/mto.2015.1126640816
   PubMed Web of Science ®Google Scholar
• Matveeva OV, Guo ZS, Senin VM, Senina AV, Shabalina SA, Chumakov PM. Oncolysis by paramyxoviruses: preclinical and clinical studies. Mol Ther Oncolytics. 2015;2:15017. doi:10.1038/mto.2015.17
   Web of Science ®Google Scholar
• Schirrmacher V. Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance. Expert Opin Biol Ther. 2015;15(12):1757–1771. doi:10.1517/14712598.2015.108800026436571
   PubMed Web of Science ®Google Scholar
• Matveeva OV, Kochneva GV, Zainutdinov SS, Ilyinskaya GV, Chumakov PM. [Oncolytic Paramyxoviruses: mechanism of Action, Preclinical and Clinical Studies]. Mol Biol (Mosk). 2018;52(3):360–379. doi:10.7868/S002689841803002329989571
   PubMed Web of Science ®Google Scholar
• Reichard KW, Lorence RM, Cascino CJ, et al. Newcastle disease virus selectively kills human tumor cells. J Surg Res. 1992;52(5):448–453.1619912
   PubMed Web of Science ®Google Scholar
• Apostolidis L, Schirrmacher V, Fournier P. Host mediated anti-tumor effect of oncolytic Newcastle disease virus after locoregional application. Int J Oncol. 2007;31(5):1009–1019.17912426
   PubMed Web of Science ®Google Scholar
• Schirrmacher V, Griesbach A, Ahlert T. Antitumor effects of Newcastle Disease Virus in vivo: local versus systemic effects. Int J Oncol. 2001;18(5):945–952. doi:10.3892/ijo.18.5.94511295039
   PubMed Web of Science ®Google Scholar
• Schulze T, Kemmner W, Weitz J, Wernecke KD, Schirrmacher V, Schlag PM. Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial. Cancer Immunol Immunother. 2009;58(1):61–69. doi:10.1007/s00262-008-0526-118488223
   PubMed Web of Science ®Google Scholar
• Lorence RM, Pecora AL, Major PP, et al. Overview of phase I studies of intravenous administration of PV701, an oncolytic virus. Curr Opin Mol Ther. 2003;5(6):618–624.14755888
   PubMedGoogle Scholar
• Laurie SA, Bell JC, Atkins HL, et al. A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization. Clin Cancer Res. 2006;12(8):2555–2562. doi:10.1158/1078-0432.CCR-05-203816638865
   PubMed Web of Science ®Google Scholar
• Lorence RM, Roberts MS, O’Neil JD, et al. Phase 1 clinical experience using intravenous administration of PV701, an oncolytic Newcastle disease virus. Curr Cancer Drug Targets. 2007;7(2):157–167.17346107
   PubMed Web of Science ®Google Scholar
• Hotte SJ, Lorence RM, Hirte HW, et al. An optimized clinical regimen for the oncolytic virus PV701. Clin Cancer Res. 2007;13(3):977–985. doi:10.1158/1078-0432.CCR-06-181717289893
   PubMed Web of Science ®Google Scholar
• Cheng X, Wang W, Xu Q, et al. Genetic modification of oncolytic newcastle disease virus for cancer therapy. J Virol. 2016;90(11):5343–5352. doi:10.1128/JVI.00136-1627009956
   PubMed Web of Science ®Google Scholar
• Beier R, Hermiston T, Mumberg D. Isolation of more potent oncolytic paramyxovirus by bioselection. Gene Ther. 2012;23(10):13.
   Google Scholar
• Institute of Laboratory Animal Resources (U.S.). Committee on Infectious Diseases of Mice and Rats. Infectious Diseases of Mice and Rats. Washington (DC): National Academy Press; 1991.
   Google Scholar
• Parker JC, Whiteman MD, Richter CB. Susceptibility of inbred and outbred mouse strains to Sendai virus and prevalence of infection in laboratory rodents. Infect Immun. 1978;19(1):123–130.203530
   PubMed Web of Science ®Google Scholar
• Slobod KS, Shenep JL, Lujan-Zilbermann J, et al. Safety and immunogenicity of intranasal murine parainfluenza virus type 1 (Sendai virus) in healthy human adults. Vaccine. 2004;22(23–24):3182–3186. doi:10.1016/j.vaccine.2004.01.05315297072
   PubMed Web of Science ®Google Scholar
• Adderson E, Branum K, Sealy RE, et al. Safety and immunogenicity of an intranasal Sendai virus-based human parainfluenza virus type 1 vaccine in 3- to 6-year-old children. Clin Vaccine Immunol. 2015;22(3):298–303. doi:10.1128/CVI.00618-1425552633
   PubMedGoogle Scholar
• Kinoh H, Inoue M, Washizawa K, et al. Generation of a recombinant Sendai virus that is selectively activated and lyses human tumor cells expressing matrix metalloproteinases. Gene Ther. 2004;11(14):1137–1145. doi:10.1038/sj.gt.330227215085175
   PubMed Web of Science ®Google Scholar
• Yonemitsu Y, Ueda Y, Kinoh H, Hasegawa M. Immunostimulatory virotherapy using recombinant Sendai virus as a new cancer therapeutic regimen. Front Biosci. 2008;13:1892–1898.17981677
   PubMed Web of Science ®Google Scholar
• Kinoh H, Inoue M. New cancer therapy using genetically-engineered oncolytic Sendai virus vector. Front Biosci. 2008;13:2327–2334.17981715
   PubMed Web of Science ®Google Scholar
• Tatsuta K, Tanaka S, Tajiri T, et al. Complete elimination of established neuroblastoma by synergistic action of gamma-irradiation and DCs treated with rSeV expressing interferon-beta gene. Gene Ther. 2009;16(2):240–251. doi:10.1038/gt.2008.16118987675
   PubMed Web of Science ®Google Scholar
• Iwadate Y, Inoue M, Saegusa T, et al. Recombinant Sendai virus vector induces complete remission of established brain tumors through efficient interleukin-2 gene transfer in vaccinated rats. Clin Cancer Res. 2005;11(10):3821–3827. doi:10.1158/1078-0432.CCR-04-148515897582
   PubMed Web of Science ®Google Scholar
• Kurooka M, Kaneda Y. Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells. Cancer Res. 2007;67(1):227–236. doi:10.1158/0008-5472.CAN-06-161517210703
   PubMed Web of Science ®Google Scholar
• Kawano H, Komaba S, Kanamori T, Kaneda Y. A new therapy for highly effective tumor eradication using HVJ-E combined with chemotherapy. BMC Med. 2007;5:28. doi:10.1186/1741-7015-5-2817883878
   PubMed Web of Science ®Google Scholar
• Kawano H, Komaba S, Yamasaki T, et al. New potential therapy for orthotopic bladder carcinoma by combining HVJ envelope with doxorubicin. Cancer Chemother Pharmacol. 2008;61(6):973–978. doi:10.1007/s00280-007-0553-117653716
   PubMed Web of Science ®Google Scholar
• Fujihara A, Kurooka M, Miki T, Kaneda Y. Intratumoral injection of inactivated Sendai virus particles elicits strong antitumor activity by enhancing local CXCL10 expression and systemic NK cell activation. Cancer Immunol Immunother. 2008;57(1):73–84. doi:10.1007/s00262-007-0351-y17602226
   PubMed Web of Science ®Google Scholar
• Kawaguchi Y, Miyamoto Y, Inoue T, Kaneda Y. Efficient eradication of hormone-resistant human prostate cancers by inactivated Sendai virus particle. Int J Cancer. 2009;124(10):2478–2487. doi:10.1002/ijc.2423419173282
   PubMed Web of Science ®Google Scholar
• Senina A, Matveeva O, Senin V, Inventors. Method for cancer immunotherapy and pharmaceutical compositions based on oncolytic non-pathogenic Sendai virus. US Patent 9,526,779 2016.
   Google Scholar
• Tatsumoto N, Arditi M, Yamashita M. Sendai virus propagation using chicken eggs. Bio Protoc. 2018;8(18). doi:10.21769/BioProtoc.3009
   Web of Science ®Google Scholar
• Giles RE, Ruddle FH. Production of Sendai virus for cell fusion. In Vitro. 1973;9(2):103–107.4357363
   PubMedGoogle Scholar
• Zainutdinov SS, Tikunov AY, Matveeva OV, Netesov SV, Kochneva GV. Complete genome sequence of the oncolytic sendai virus strain Moscow. Genome Announc. 2016;4(4). doi:10.1128/genomeA.00933-16
   Google Scholar
• Dalldorf G, Gifford R. Clinical and epidemiologic observations of Coxsackie-virus infection. N Engl J Med. 1951;244(23):868–873. doi:10.1056/NEJM19510607244230214843332
   PubMed Web of Science ®Google Scholar
• Mahy BWJ. Classification and general propeties. In: Bendinelli M, Friedman H, eds. Coxsackieviruses. A General Update. New York City, USA: Springer US; 1988: 1–18.doi:10.1007/978-1-4757-0247-7
   Google Scholar
• Shafren DR, Au GG, Nguyen T, et al. Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, coxsackievirus a21. Clin Cancer Res. 2004;10(1 Pt 1):53–60.14734451
   PubMed Web of Science ®Google Scholar
• Au GG, Lindberg AM, Barry RD, Shafren DR. Oncolysis of vascular malignant human melanoma tumors by Coxsackievirus A21. Int J Oncol. 2005;26(6):1471–1476. doi:10.3892/ijo.26.6.147115870858
   PubMed Web of Science ®Google Scholar
• Skelding KA, Barry RD, Shafren DR. Enhanced oncolysis mediated by Coxsackievirus A21 in combination with doxorubicin hydrochloride. Invest New Drugs. 2012;30(2):568–581. doi:10.1007/s10637-010-9614-021170760
   PubMed Web of Science ®Google Scholar
• Au GG, Beagley LG, Haley ES, Barry RD, Shafren DR. Oncolysis of malignant human melanoma tumors by Coxsackieviruses A13, A15 and A18. Virol J. 2011;8:22. doi:10.1186/1743-422X-8-2221241513
   PubMed Web of Science ®Google Scholar
• Bradley S, Jakes AD, Harrington K, Pandha H, Melcher A, Errington-Mais F. Applications of coxsackievirus A21 in oncology. Oncolytic Virother. 2014;3:47–55. doi:10.2147/OV.S5632227512662
   PubMedGoogle Scholar
• Agarwala SS. The role of intralesional therapies in Melanoma. Oncology (Williston Park). 2016;30(5):436–441.27188674
   PubMed Web of Science ®Google Scholar
• Miyamoto S, Inoue H, Nakamura T, et al. Coxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinoma. Cancer Res. 2012;72(10):2609–2621. doi:10.1158/0008-5472.CAN-11-318522461509
   PubMed Web of Science ®Google Scholar
• Miyamoto S, Sagara M, Kohara H, Tani K. Oncolytic coxsackievirus therapy as an immunostimulator. Rinsho Ketsueki. 2017;58(8):977–982. doi:10.11406/rinketsu.58.97728883283
   PubMedGoogle Scholar
• Shafren DR, Dorahy DJ, Ingham RA, Burns GF, Barry RD. Coxsackievirus A21 binds to decay-accelerating factor but requires intercellular adhesion molecule 1 for cell entry. J Virol. 1997;71(6):4736–4743.9151867
   PubMed Web of Science ®Google Scholar
• Johansson ES, Xing L, Cheng RH, Shafren DR. Enhanced cellular receptor usage by a bioselected variant of coxsackievirus a21. J Virol. 2004;78(22):12603–12612. doi:10.1128/JVI.78.22.12603-12612.200415507647
   PubMed Web of Science ®Google Scholar
• Polacek C, Ekstrom JO, Lundgren A, Lindberg AM. Cytolytic replication of coxsackievirus B2 in CAR-deficient rhabdomyosarcoma cells. Virus Res. 2005;113(2):107–115. doi:10.1016/j.virusres.2005.04.02115964091
   PubMed Web of Science ®Google Scholar
• Pan J, Narayanan B, Shah S, et al. Single amino acid changes in the virus capsid permit coxsackievirus B3 to bind decay-accelerating factor. J Virol. 2011;85(14):7436–7443. doi:10.1128/JVI.00503-1121561916
   PubMed Web of Science ®Google Scholar
• Reagan KJ, Goldberg B, Crowell RL. Altered receptor specificity of coxsackievirus B3 after growth in rhabdomyosarcoma cells. J Virol. 1984;49(3):635–640.6321753
   PubMed Web of Science ®Google Scholar
• Smura T, Natri O, Ylipaasto P, et al. Enterovirus strain and type-specific differences in growth kinetics and virus-induced cell destruction in human pancreatic duct epithelial HPDE cells. Virus Res. 2015;210:188–197. doi:10.1016/j.virusres.2015.08.00326260332
   PubMed Web of Science ®Google Scholar
• Svyatchenko VA, Ternovoy VA, Kiselev NN, et al. Bioselection of coxsackievirus B6 strain variants with altered tropism to human cancer cell lines. Arch Virol. 2017;162(11):3355–3362. doi:10.1007/s00705-017-3492-028766058
   PubMed Web of Science ®Google Scholar
• Montmayeur AM, Ng TF, Schmidt A, et al. High-throughput next-generation sequencing of polioviruses. J Clin Microbiol. 2017;55(2):606–615. doi:10.1128/JCM.02121-1627927929
   PubMed Web of Science ®Google Scholar
• Sabine AB, Boulger LR. History of Sabin attenuated poliovirus oral live vaccine strains. J Biol Stand. 1973;1(2):115–118. doi:10.1016/0092-1157(73)90048-6
   Google Scholar
• Bandyopadhyay AS, Garon J, Seib K, Orenstein WA. Polio vaccination: past, present and future. Future Microbiol. 2015;10(5):791–808. doi:10.2217/fmb.15.1925824845
   PubMed Web of Science ®Google Scholar
• Brown MC, Dobrikova EY, Dobrikov MI, et al. Oncolytic polio virotherapy of cancer. Cancer. 2014;120(21):3277–3286. doi:10.1002/cncr.2886224939611
   PubMed Web of Science ®Google Scholar
• Bleeker FE, Molenaar RJ, Leenstra S. Recent advances in the molecular understanding of glioblastoma. J Neurooncol. 2012;108(1):11–27. doi:10.1007/s11060-011-0793-022270850
   PubMed Web of Science ®Google Scholar
• Desjardins A, Gromeier M, Herndon JE 2nd, et al. Recurrent glioblastoma treated with recombinant poliovirus. N Engl J Med. 2018;379(2):150–161. doi:10.1056/NEJMoa171643529943666
   PubMed Web of Science ®Google Scholar
• Thompson EM, Brown M, Dobrikova E, et al. Poliovirus receptor (CD155) expression in pediatric brain tumors mediates oncolysis of medulloblastoma and pleomorphic xanthoastrocytoma. J Neuropathol Exp Neurol. 2018;77(8):696–702. doi:10.1093/jnen/nly04529878245
   PubMed Web of Science ®Google Scholar
• Holl EK, Brown MC, Boczkowski D, et al. Recombinant oncolytic poliovirus, PVSRIPO, has potent cytotoxic and innate inflammatory effects, mediating therapy in human breast and prostate cancer xenograft models. Oncotarget. 2016;7(48):79828–79841. doi:10.18632/oncotarget.1297527806313
   PubMedGoogle Scholar
• Brown MC, Gromeier M. Cytotoxic and immunogenic mechanisms of recombinant oncolytic poliovirus. Curr Opin Virol. 2015;13:81–85. doi:10.1016/j.coviro.2015.05.00726083317
   PubMed Web of Science ®Google Scholar
• Brown MC, Holl EK, Boczkowski D, et al. Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen-specific CTLs. Sci Transl Med. 2017;9:408. doi:10.1126/scitranslmed.aan4220
   Web of Science ®Google Scholar
• Walton RW, Brown MC, Sacco MT, Gromeier M. Engineered oncolytic poliovirus PVSRIPO subverts MDA5-dependent innate immune responses in cancer cells. J Virol. 2018;92(19). doi:10.1128/JVI.02230-17
   Web of Science ®Google Scholar
• Gromeier M, Nair SK. Recombinant poliovirus for cancer immunotherapy. Annu Rev Med. 2018;69:289–299. doi:10.1146/annurev-med-050715-10465529414253
   PubMed Web of Science ®Google Scholar
• Sanjuan R, Grdzelishvili VZ. Evolution of oncolytic viruses. Curr Opin Virol. 2015;13:1–5. doi:10.1016/j.coviro.2015.01.01425699475
   PubMed Web of Science ®Google Scholar
• Kew OM, Nottay BK, Hatch MH, Nakano JH, Obijeski JF. Multiple genetic changes can occur in the oral poliovaccines upon replication in humans. J Gen Virol. 1981;56(Pt 2):337–347. doi:10.1099/0022-1317-56-2-3376273502
   PubMed Web of Science ®Google Scholar
• Famulare M, Chang S, Iber J, et al. Sabin vaccine reversion in the field: a comprehensive analysis of sabin-like poliovirus isolates in Nigeria. J Virol. 2016;90(1):317–331. doi:10.1128/JVI.01532-1526468545
   PubMed Web of Science ®Google Scholar
• Dobrikova EY, Broadt T, Poiley-Nelson J, et al. Recombinant oncolytic poliovirus eliminates glioma in vivo without genetic adaptation to a pathogenic phenotype. Mol Ther. 2008;16(11):1865–1872. doi:10.1038/mt.2008.18418766173
   PubMed Web of Science ®Google Scholar
• Lyles DS, Kusmin IV, Rupprecht CE. Rhabdoviridae In: Fields BN, Knipe DM, Howley PM, eds. Fields Virology, Vol. 1, Chapter 31, 6th ed. Philadelphia, USA: Walters Kluwer, Lippincott Williams & Wilkins; 2013: 885–922
   Google Scholar
• Felt SA, Grdzelishvili VZ. Recent advances in vesicular stomatitis virus-based oncolytic virotherapy: a 5-year update. J Gen Virol. 2017. doi:10.1099/jgv.0.000980
   Web of Science ®Google Scholar
• Melzer MK, Lopez-Martinez A, Altomonte J. Oncolytic vesicular stomatitis virus as a viro-immunotherapy: defeating cancer with a “Hammer” and “Anvil”. Biomedicines. 2017;5(1). doi:10.3390/biomedicines5010008
   Web of Science ®Google Scholar
• Gao Y, Whitaker-Dowling P, Watkins SC, Griffin JA, Bergman I. Rapid adaptation of a recombinant vesicular stomatitis virus to a targeted cell line. J Virol. 2006;80(17):8603–8612. doi:10.1128/JVI.00142-0616912309
   PubMed Web of Science ®Google Scholar
• Wollmann G, Tattersall P, van den Pol AN. Targeting human glioblastoma cells: comparison of nine viruses with oncolytic potential. J Virol. 2005;79(10):6005–6022. doi:10.1128/JVI.79.10.6005-6022.200515857987
   PubMed Web of Science ®Google Scholar
• Garijo R, Hernandez-Alonso P, Rivas C, Diallo JS, Sanjuan R. Experimental evolution of an oncolytic vesicular stomatitis virus with increased selectivity for p53-deficient cells. PLoS One. 2014;9(7):e102365. doi:10.1371/journal.pone.010236525010337
   PubMed Web of Science ®Google Scholar
• Lauring AS, Andino R. Quasispecies theory and the behavior of RNA viruses. PLoS Pathog. 2010;6(7):e1001005. doi:10.1371/journal.ppat.100097520661479
   PubMed Web of Science ®Google Scholar
• Borderia AV, Rozen-Gagnon K, Vignuzzi M. Fidelity variants and RNA quasispecies. Curr Top Microbiol Immunol. 2016;392:303–322. doi:10.1007/82_2015_48326499340
   PubMed Web of Science ®Google Scholar
• Duffy S. Why are RNA virus mutation rates so damn high? PLoS Biol. 2018;16(8):e3000003. doi:10.1371/journal.pbio.300000330102691
   PubMed Web of Science ®Google Scholar